{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:25:50Z","timestamp":1648751150050},"reference-count":15,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1272\/jnms.83.81","type":"journal-article","created":{"date-parts":[[2016,5,15]],"date-time":"2016-05-15T22:06:37Z","timestamp":1463349997000},"page":"81-86","source":"Crossref","is-referenced-by-count":1,"title":["Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer"],"prefix":"10.1272","volume":"83","author":[{"given":"Maki","family":"Nakai","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, &quot;pure&quot; antiestrogen. Cancer 2000; 89: 817-825.","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.3.CO;2-Y"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. McDonnell DP, Wardell SE: The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol 2010; 10: 620-628.","DOI":"10.1016\/j.coph.2010.09.007"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Mu\u00f1oz C, Vega E, Calder\u00f3n MJ, Sancho B, Cortes-Funes H: The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast 2014; 23: 201-208.","DOI":"10.1016\/j.breast.2014.01.016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28: 4594-4600.","DOI":"10.1200\/JCO.2010.28.8415"},{"key":"5","unstructured":"5. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M: Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014; 106: 1-7."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pritchard KI: Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 2008; 112: 718-722.","DOI":"10.1002\/cncr.23189"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, Akazawa K, Abe O: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 2005; 23: 2172-2184.","DOI":"10.1200\/JCO.2005.02.158"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, Doihara H, Miyoshi S: Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci 2011; 102: 2038-2042.","DOI":"10.1111\/j.1349-7006.2011.02050.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Robertson JF, Harrison M: Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 2004; 90(Suppl 1): S7-S10.","DOI":"10.1038\/sj.bjc.6601630"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bol\u00e4nder J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.","DOI":"10.1001\/jama.2009.1420"},{"key":"11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clbc.2013.09.003","volume":"14","author":"LS Schwartzberg","year":"2014","unstructured":"11. Schwartzberg LS, Wang G, Somer BG, Blakely LJ, Wheeler BM, Walker MS, Stepanski EJ, Houts AC: Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clinical Breast Cancer 2014; 14: 13-19.","journal-title":"Clinical Breast Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/1526-8209","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized &apos;FIRST&apos; study. Breast Cancer Res Treat 2012; 136: 503-511.","DOI":"10.1007\/s10549-012-2192-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S: Kinki Breast Cancer Study Group: Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010; 56: 166-170.","DOI":"10.1159\/000313531"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS: Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011; 29: 4498-4504.","DOI":"10.1200\/JCO.2010.33.9101"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Leonard R, Hennessy BT, Blum JL, O&apos;Shaughnessy J: Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin Breast Cancer 2011; 11: 349-356.","DOI":"10.1016\/j.clbc.2011.06.005"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/83\/2\/83_81\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:42:53Z","timestamp":1498311773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/83\/2\/83_81\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.83.81","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}